- Home
- NDSN vs ASND Comparison
NDSN vs ASND Comparison
Compare NDSN & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDSN | ASND |
|---|---|---|
| Founded | 1935 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 13.6B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NDSN | ASND |
|---|---|---|
| Price | $267.80 | $229.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $320.80 | $278.80 |
| AVG Volume (30 Days) | 366.9K | ★ 718.2K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 4.93 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,254,668,000.00 | N/A |
| Revenue This Year | $7.75 | $98.02 |
| Revenue Next Year | $4.89 | $43.13 |
| P/E Ratio | $115.01 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $165.03 | $124.06 |
| 52 Week High | $305.28 | $248.60 |
Technical Indicators
Market Signals| Indicator | NDSN | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 49.46 |
| Support Level | $265.19 | $190.49 |
| Resistance Level | $275.43 | $245.30 |
| Average True Range (ATR) | 6.28 | 9.40 |
| MACD | -3.59 | -0.89 |
| Stochastic Oscillator | 10.41 | 35.92 |
Price Performance
Historical ComparisonAbout NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.8 billion in revenue in its fiscal 2025.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.